Ignite Creation Date:
2024-10-26 @ 3:39 PM
Last Modification Date:
2024-10-26 @ 3:39 PM
Study NCT ID:
NCT06582888
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-08-21
Brief Title:
Advancing VR-based Attentional Bias As a Biomarker for Tobacco Use Disorder
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Advancing VR-based Attentional Bias As a Biomarker for Tobacco Use Disorder
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
VR
Brief Summary:
The proposed project will include enrollment of 200 daily tobacco cigarette users ages 22 from the San Diego community Participants will be assessed on the VR Nicotine Cue Exposure paradigm then randomized stratified on age and sex to receive varenicline target dose 1mg twice daily or placebo n per group100 total N200 Following eight days of titration participants will be assessed again on the VR Nicotine Cue Exposure paradigm They will then be followed via mobile assessments for eight days on target dose of varenicline and 30-days post assessment by phone to assess short-term nicotine use behaviors
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None